Cytomegalovirus Management in Transplant Recipients

Cytomegalovirus is an ubiquitous herpesvirus that poses a significant threat to solid organ and haematopoietic stem cell transplant recipients. Primary infection, reinfection or reactivation may lead to viraemia, end-organ disease and indirect immunomodulatory effects that increase graft rejection, morbidity and mortality. Management strategies centre on risk stratification by donor–recipient serostatus, routine surveillance of viral load and tailored antiviral interventions. Prophylactic regimens with agents such as valganciclovir or letermovir have transformed early prevention, whereas preemptive therapy guided by quantitative PCR allows timely treatment with reduced drug exposure. However, long-term prophylaxis carries risks of haematological toxicity and the emergence of resistant CMV strains, highlighting the need for alternative approaches. Immunological monitoring of CMV-specific T-cell responses and adoptive cellular therapies have shown promise in restoring antiviral immunity without exacerbating graft-versus-host disease. Advances in understanding viral latency, reactivation mechanisms and host immune correlates have informed novel vaccine candidates and pharmacodynamic biomarkers, which are currently under evaluation in clinical trials. This integrated framework of virological surveillance, pharmacological prophylaxis and immunotherapeutic interventions underpins the global effort to improve outcomes in transplant recipients at risk of CMV-related complications.

Research from Nature Portfolio

Recent reviews have synthesised insights into CMV pathogenesis in immunocompromised hosts, elucidating the interplay between viral latency, reactivation triggers and host immunity. Serial viral load measurements have been established as a cornerstone for early detection and therapeutic monitoring, guiding personalised interventions. Detailed characterisation of viral immune evasion strategies has spurred the development of novel antivirals that target distinct stages of the CMV replication cycle. Moreover, emerging evidence on immune correlates of protection has informed the rational design of candidate vaccines and immunomodulatory agents, with early-phase trials now assessing their capacity to prevent viraemia and severe disease in high-risk transplant populations.

Cytomegalovirus Management in Transplant Recipients publication trend

The graph below shows the total number of articles in cytomegalovirus management in transplant recipients across all publications each year (not limited to Nature Index journals).

Technical terms

Latency: A dormant state in which CMV persists in host cells without active replication.

Reactivation: The process by which latent CMV resumes replication, potentially causing disease.

Prophylaxis: Preventive antiviral treatment administered to transplant recipients to avert CMV infection or disease.

Preemptive therapy: Antiviral treatment initiated based on early viral load detection rather than clinical symptoms.

Viral load: The quantity of CMV DNA in blood, measured by PCR to guide management.

Adoptive T-cell therapy: The infusion of CMV-specific T lymphocytes to restore antiviral immunity.

Serostatus: The presence or absence of CMV antibodies in donor or recipient, indicating prior exposure or infection.

Allogeneic transplantation: Transplantation of cells or organs from a genetically distinct donor.

References

1. Third party CMV viral specific T-cells for refractory CMV viremia and disease after hematopoietic transplant. Journal of Clinical Investigation (2023).
2. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nature Reviews Microbiology (2021).
3. The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients. American Journal of Transplantation (2010).
4. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation. Clinical Infectious Diseases (2019).
5. Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy. American Journal of Transplantation (2012).
6. Clinical immune‐monitoring strategies for predicting infection risk in solid organ transplantation. Clinical & Translational Immunology (2014).
7. Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Frontiers in Microbiology (2019).